O
WX

OppenheimerFunds’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

OppenheimerFunds’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,952,017
Closed -$171M – 1792
2015
Q3 		$171M Buy
3,952,017
+1,732,099
+78% +$73.1M 0.23% 111
2015
Q2 		$93.8M Buy
2,219,918
+992,916
+81% +$41.9M 0.11% 223
2015
Q1 		$47.6M Buy
1,227,002
+55,068
+5% +$2.12M 0.05% 383
2014
Q4 		$39.5M Hold
1,171,934
– – 0.04% 416
2014
Q3 		$41M Buy
1,171,934
+128,494
+12% +$4.4M 0.05% 384
2014
Q2 		$34.3M Buy
1,043,440
+123,800
+13% +$4.24M 0.04% 441
2014
Q1 		$33.9M Buy
919,640
+33,590
+4% +$1.23M 0.04% 439
2013
Q4 		$34M Sell
886,050
-365,450
-29% -$11.5M 0.04% 433
2013
Q3 		$34.3M Buy
1,251,500
+625,750
+100% +$14.8M 0.02% 576
2013
Q2 		$13.1M Buy
+625,750
New +$12.2M 0.02% 624

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

OppenheimerFunds's WX Position: Q4 2015 in Review

OppenheimerFunds sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 3,952,017 shares — an estimated $171M sold.

OppenheimerFunds first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $171M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • OppenheimerFunds reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • OppenheimerFunds sold 3,952,017 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $171M.
  • OppenheimerFunds first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • OppenheimerFunds's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $171M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on OppenheimerFunds's 13F filing for Q4 2015, filed 5 Feb 2016.